Bridget E. Bunner

Array ( [id] => 11690912 [patent_doc_number] => 20170166627 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'FIBRONECTIN BASED SCAFFOLD PROTEINS HAVING IMPROVED STABILITY' [patent_app_type] => utility [patent_app_number] => 15/385222 [patent_app_country] => US [patent_app_date] => 2016-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 28693 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15385222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11542668 [patent_doc_number] => 20170096493 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-06 [patent_title] => 'Anti Human Notch4 Antibody' [patent_app_type] => utility [patent_app_number] => 15/382821 [patent_app_country] => US [patent_app_date] => 2016-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 16953 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15382821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12999967 [patent_doc_number] => 10023641 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-17 [patent_title] => Anti-TIE2 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 15/373903 [patent_app_country] => US [patent_app_date] => 2016-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 14288 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15373903 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12448614 [patent_doc_number] => 09982058 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-29 [patent_title] => Anti-JAG1 antibody compositions and methods for treatment of hepatic cancers [patent_app_type] => utility [patent_app_number] => 15/373275 [patent_app_country] => US [patent_app_date] => 2016-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 71 [patent_no_of_words] => 33191 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15373275 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866200 [patent_doc_number] => 20170233486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'POLYNUCLEOTIDES ENCODING ANTI-NOTCH1 NRR ANTIBODY POLYPEPTIDES' [patent_app_type] => utility [patent_app_number] => 15/359098 [patent_app_country] => US [patent_app_date] => 2016-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 58367 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15359098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11851726 [patent_doc_number] => 20170226218 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'Method for In Vivo Expansion of T Regulatory Cells' [patent_app_type] => utility [patent_app_number] => 15/357891 [patent_app_country] => US [patent_app_date] => 2016-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 20588 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15357891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11471259 [patent_doc_number] => 20170058041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-02 [patent_title] => 'Toll-Like Receptor 3 Antagonists' [patent_app_type] => utility [patent_app_number] => 15/345860 [patent_app_country] => US [patent_app_date] => 2016-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 54 [patent_no_of_words] => 34869 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15345860 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12641286 [patent_doc_number] => 20180105593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => METHODS AND COMPOSITIONS FOR USING MHC CLASS II INVARIANT CHAIN POLYPEPTIDES AS A RECEPTOR FOR MACROPHAGE MIGRATION INHIBITORY FACTOR [patent_app_type] => utility [patent_app_number] => 15/339778 [patent_app_country] => US [patent_app_date] => 2016-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6505 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15339778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11604079 [patent_doc_number] => 20170121380 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-04 [patent_title] => 'Composition for Preventing or Treating Fatty Liver or Insulin Resistance Syndrome Including Extracellular Domain of Delta-Like 1 Homolog' [patent_app_type] => utility [patent_app_number] => 15/337208 [patent_app_country] => US [patent_app_date] => 2016-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 8867 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15337208 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11690916 [patent_doc_number] => 20170166632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'Therapeutic Combination and Methods of Treatment With A DLL4 Antagonist and an Anti-Hypertensive Agent' [patent_app_type] => utility [patent_app_number] => 15/336272 [patent_app_country] => US [patent_app_date] => 2016-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 13812 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15336272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11743958 [patent_doc_number] => 20170198031 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-13 [patent_title] => 'NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/298527 [patent_app_country] => US [patent_app_date] => 2016-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 54930 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15298527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11714906 [patent_doc_number] => 20170183405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-29 [patent_title] => 'NOTCH1 RECEPTOR BINDING AGENTS AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/291334 [patent_app_country] => US [patent_app_date] => 2016-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 34036 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15291334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12254236 [patent_doc_number] => 09926372 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-27 [patent_title] => 'Methods and compositions for modulation of blood-neural barrier' [patent_app_type] => utility [patent_app_number] => 15/286818 [patent_app_country] => US [patent_app_date] => 2016-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 17734 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15286818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11382912 [patent_doc_number] => 20170008967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-12 [patent_title] => 'ANTI-TLR4 ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/276202 [patent_app_country] => US [patent_app_date] => 2016-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 33325 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15276202 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13440787 [patent_doc_number] => 20180271936 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => METHOD AND COMPOSITION FOR TREATMENT OF HAIR LOSS [patent_app_type] => utility [patent_app_number] => 15/763356 [patent_app_country] => US [patent_app_date] => 2016-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6765 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15763356 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11350259 [patent_doc_number] => 20160368999 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-22 [patent_title] => 'ANTIBODY FORMULATION' [patent_app_type] => utility [patent_app_number] => 15/254351 [patent_app_country] => US [patent_app_date] => 2016-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11780 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15254351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16999455 [patent_doc_number] => 11078246 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-03 [patent_title] => Peptides binding to Bfl-1 [patent_app_type] => utility [patent_app_number] => 15/752358 [patent_app_country] => US [patent_app_date] => 2016-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 59 [patent_no_of_words] => 20401 [patent_no_of_claims] => 76 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15752358 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11324991 [patent_doc_number] => 20160355603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-08 [patent_title] => 'Methods and Compositions for the Treatment of Pancreatic Cancer' [patent_app_type] => utility [patent_app_number] => 15/244833 [patent_app_country] => US [patent_app_date] => 2016-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 17684 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15244833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11491507 [patent_doc_number] => 20170065692 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-09 [patent_title] => 'USE OF TOLL-LIKE RECEPTOR AGONIST FOR TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 15/241757 [patent_app_country] => US [patent_app_date] => 2016-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 16506 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15241757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11436111 [patent_doc_number] => 20170037130 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'ANTIBODY CONSTRUCTS FOR DLL3 AND CD3' [patent_app_type] => utility [patent_app_number] => 15/225107 [patent_app_country] => US [patent_app_date] => 2016-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 53775 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15225107 [rel_patent_id] =>[rel_patent_doc_number] =>)